These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25954247)

  • 1. Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival.
    Alexandrova EM; Marchenko ND
    Front Endocrinol (Lausanne); 2015; 6():53. PubMed ID: 25954247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
    Li D; Yallowitz A; Ozog L; Marchenko N
    Cell Death Dis; 2014 Apr; 5(4):e1194. PubMed ID: 24763051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
    Schulz-Heddergott R; Moll UM
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.
    Alvarado-Ortiz E; de la Cruz-López KG; Becerril-Rico J; Sarabia-Sánchez MA; Ortiz-Sánchez E; García-Carrancá A
    Front Cell Dev Biol; 2020; 8():607670. PubMed ID: 33644030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 in Cancer Progression and Targeted Therapies.
    Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
    Front Oncol; 2020; 10():595187. PubMed ID: 33240819
    [No Abstract]   [Full Text] [Related]  

  • 9. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
    Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
    Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
    Zhang Y; Hu Y; Fang JY; Xu J
    Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members.
    Kaida A; Iwakuma T
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
    Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
    Front Oncol; 2021; 11():642603. PubMed ID: 34178628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulators of Oncogenic Mutant TP53 Gain of Function.
    Yamamoto S; Iwakuma T
    Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status.
    Nguyen CH; Lang BJ; Chai RC; Vieusseux JL; Kouspou MM; Price JT
    Biochem J; 2013 Jun; 452(2):321-9. PubMed ID: 23510323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-associated mutant p53 drives the Warburg effect.
    Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
    Nat Commun; 2013; 4():2935. PubMed ID: 24343302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mutant p53 in cancer: the latest insights.
    Di Agostino S; Fontemaggi G; Strano S; Blandino G; D'Orazi G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):290. PubMed ID: 31277687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.
    Nishikawa S; Iwakuma T
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
    Gomes S; Bosco B; Loureiro JB; Ramos H; Raimundo L; Soares J; Nazareth N; Barcherini V; Domingues L; Oliveira C; Bisio A; Piazza S; Bauer MR; Brás JP; Almeida MI; Gomes C; Reis F; Fersht AR; Inga A; Santos MMM; Saraiva L
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.